Indian Government Seals Deal For Biological-E COVID vaccines

India has suffered a disastrous second wave of COVID-19 that is slowly abating. To strengthen the fight against coronavirus that has hit the nation. The Indian government has signed a deal for 300 million doses of Biological-E COVID vaccines. The Union health ministry said it has inked a deal with domestic vaccine maker Biological-E for 15 billion rupees ($205.62 million).

The health ministry further added that the vaccine is currently undergoing phase-3 clinical trials. It is likely to be available in the next few months.

According to a Reuters report, Biological E Limited is a Hyderabad-based company. It has signed a deal with Canadian biotechnology company Providence Therapeutics Holdings Inc for its COVID-19 vaccine. The vaccine being developed is an RBD protein subunit vaccine. Biological-E will run a clinical trial of Providence’s vaccine in India and also seek emergency use approval.

As reported by sources to Zee, as per the new rules announced by the Ministry Of Health and Family Welfare, any firm that has received approval for their vaccine, in their country can get the Emergency Use Authorisation (EUA). They can conduct trials parallelly while the vaccine is being administered to the masses.

Earlier in May, Biological-E Managing Director Mahima Datla had told Reuters that the company plans to produce 75 million to 80 million doses a month from August. The vaccine is likely to hit the Indian market soon.

The government has assured that India will have enough COVID-19 vaccine doses to inoculate up to one crore people per day by mid-July or early August.

Also Read: SBI Report: COVID-19 Third Wave May Last For 98 Days; Vaccination Important